Coronado forms Mustang, pays City of Hope up to $40mm for CART IP; license expanded
Executive Summary
Coronado Biosciences Inc. formed another division, Mustang Therapeutics Inc., which will develop IP in-licensed from the City of Hope focused on chimeric antigen receptor T-cell (CART) therapies for cancer.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Immuno-Oncology
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice